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Abstract
Background: Although the safety and efficacy of left atrial (LA) appendage (LAA) closure (LAAC) in 
nonvalvular atrial fibrillation (NVAF) patients have been well documented in randomized controlled 
trials and real-world experience, there are limited data in the literature about the impact of LAAC on 
cardiac remodeling. The aim of the study was to examine the impact of LAAC on cardiac functional 
and structural remodeling in NVAF patients.
Methods: Between March 2014 and November 2016, 47 NVAF patients who underwent LAAC were 
included in this study (LAAC group). A control group (non-LAAC group) was formed from 141 NVAF 
patients without LAAC using propensity score matching. The difference-in-difference analysis was 
used to evaluate the difference in cardiac remodeling between the two groups at baseline and follow-up 
evaluations.
Results: The LAAC group had a larger increase in LA dimension, volume and volume index than the 
non-LAAC group (+3.9 mm, p = 0.001; +9.7 mL, p = 0.006 and +5.9 mL/m2, p = 0.011, respec-
tively). Besides, a significant increase in E and E/e’ ratio was also observed in the LAAC group (+14.6 
cm/s, p = 0.002 and +2.3, p = 0.028, respectively). Compared with the non-LAAC group, left ventricu-
lar (LV) ejection fraction and fractional shortening decreased in LAAC patients, but were statistically 
insignificant (–3.5%, p = 0.109 and –2.0%, p = 0.167, respectively). 
Conclusions: There were significant increases in LA size and LV filling pressure among NVAF pa-
tients after LAAC. These impacts of LAAC on cardiac functional and structural remodeling may have 
some clinical implications that need to be addressed in future studies. (Cardiol J 2019; 26, 5: 519–528)
Key words: left atrial appendage closure, atrial fibrillation, stroke prevention, diastolic 
function, systolic function, cardiac remodeling, difference-in-difference analysis
Introduction
Thrombus formed inside the left atrial (LA) 
appendage (LAA) is the most common cause of 
ischemic stroke in nonvalvular atrial fibrillation 
(NVAF) patients [1–3]. Although oral anticoagulant 
(OAC) has been shown to be effective in reducing 
the incidence of ischemic stroke, it also increases 
the risk of hemorrhage complications in these pa-
tients [4–6]. Percutaneous LAA closure (LAAC) is 
considered to be effective both in decreasing the 
risk of stroke and lowering the bleeding complica-
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tion of OAC in NVAF patients with concomitant 
high bleeding risk [7–9]. 
Left atrial appendage has several important 
mechanical and endocrine functions regarding 
unique anatomical and physiological properties 
[10, 11]. When LA volume or pressure overload 
happens, LAA becomes a significant reservoir 
chamber due to its distensible ability [12]. LAA 
removal resulted in increased LA size, LA pressure 
and decreased cardiac output in animals [13]. The 
removal may be particularly harmful with existing 
heart failure because it would further reduce the 
cardiac output and promote heart failure. Besides, 
LAA is also known as the source of atrial natriuretic 
peptide (ANP) in the human heart. The concentra-
tion of ANP is much higher in LAA walls than in 
the rest of the atrial free wall and in the ventri-
cles [11]. Patients with LAA removal were found 
to have a significantly lower ANP secretion and 
concomitant increase in salt and water retention 
[14, 15]. Interestingly, percutaneous LAAC with 
devices for ischemic stroke prevention has been 
shown to be associated with a significant reduc-
tion in plasma ANP [16, 17]. Therefore, both LAA 
mechanical and endocrine functions will be altered 
after LAAC. These changes can further affect the 
cardiac function and structure. 
Although the safety and efficacy of LAAC in 
NVAF patients are well documented, there are 
limited data in the literature about the impact 
of percutaneous LAAC on cardiac functional and 
structural remodeling.
Methods
Patients
The data of NVAF patients, who underwent 
LAAC between March 2014 and November 2016 
(LAAC group), were retrospectively collected 
before LAAC (baseline) and 12 months after the 
procedure (follow-up). All of these patients had per-
manent atrial fibrillation (AF,) high risk of ischemic 
stroke (CHA2DS2-VASc score ≥ 2), and contraindi-
cation to OAC or high risk of bleeding (HAS-BLED 
score ≥ 3). A control group (non-LAAC group) was 
formed by including NVAF patients without LAAC 
that were being followed-up at the documented 
institute. For each case in the LAAC group, three 
control subjects were matched (1:3 style) based on 
sex, age and ejection fraction (EF) using propensity 
score matching. Patients with incomplete data or 
with the following conditions were excluded from 
the study: device embolization, significant residual 
peri-device leak (≥ 5 mm) detected on follow-up 
transesophageal echocardiography (TEE), mitral 
valve stenosis, proximal AF or AF that was con-
verted to sinus rhythm during follow-up, prosthetic 
valve, atrial septal defect, dilated cardiomyopathy, 
and moderate to severe mitral valve regurgitation.
Devices
The devices used for LAAC were either Car-
diac Plug or Amulet (St. Jude Medical, St. Paul, 
Minnesota, USA). Cardiac Plug is a self-expanding 
device that is made from nitinol wire mesh with 
a lobe and a disc connected via a waist. The design is 
aimed at sealing the body and ostium of the LAA. 
The lobe is usually implanted 10 mm inside the 
LAA body, and the anchoring mechanism is aided 
by stabilizing wires. The Amulet (or Cardiac Plug 2) 
is the second generation of the Cardiac Plug, which 
retains the basic structure of Cardiac Plug with 
some modifications for better performance and 
sealing (Fig. 1). 
Procedure
Before the procedure, TEE was performed to 
assess LAA size, morphology and to confirm the 
absence of thrombus in LA and LAA. After trans-
septal puncture, heparin was administered to achieve 
an active clotting time of 250–350 s [18]. At least 
2 standard projections (RAO cranial and RAO caudal) 
were performed to obtain good visualization of the 
LAA. Fluoroscopy and TEE (or intra-cardiac echocar-
diography) imaging were used to re-evaluate the LAA 
and to select an appropriate device for each patient. 
The device size was chosen to be at least 20% larger 
than the measured diameter at the landing zone [18]. 
TEE (or intra-cardiac echocardiography) was used to 
check for the compression, positioning, stability of 
the device, peri-device leak and the relationship be-
tween device and adjacent structures. Transthoracic 
echocardiography, electrocardigraphy and chest X-ray 
were performed within 24 h after the procedure to 
rule out complications. All patients were discharged 
with dual antiplatelet therapy. The follow-up echo-
cardiography was performed at 1 and 6 months, and 
then every 12 months after the procedure.
Echocardiography 
Echocardiography was performed using the 
Philips EPIQ 7 ultrasound system for cardiology 
(Philips Corporation, MA, USA) with an S8-3 sec-
tor array transducer. All acquired data were stored 
in digital files for offline interpretation and were 
then evaluated by a single experienced expert in 
cardiovascular imaging. The measurement and 
quantification followed the recommendations from 
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the American Society of Echocardiography [19, 20]. 
The parameters were obtained by averaging five 
consecutive cardiac cycles. In this study, baseline 
and follow-up echocardiography data were collected 
in both LAAC and non-LAAC groups.
In the M-mode, the following parameters were 
measured at parasternal long axis view: left ven-
tricular internal dimension at end diastole (LVDd), 
left ventricular internal dimension at end systole 
(LVDs), interventricular septum thickness at end 
diastole (IVSd), interventricular septal thickness at 
end systole (IVSs), left ventricular posterior wall 
thickness at end diastole (LVPWd), left ventricular 
posterior wall thickness at end systole (LVPWs), 
left atrial dimension (LAD). The Teichholz method 
was used to calculate EF (the M-mode left ventricu-
lar ejection fraction). Cube formula was used to 
estimate left ventricular mass (LVM) and left ven-
tricular mass indexed to body surface area (LVMI). 
Tricuspid annular plane systolic excursion (TAPSE) 
was measured on apical four-chamber views.
Pulse-wave Doppler was used to measure E 
(peak velocity of early diastolic trans-mitral flow) 
and deceleration time of early diastolic trans-mitral 
flow (DT). Tissue Doppler was used to measure e’ 
(peak velocity of early diastolic mitral annular mo-
tion). The E/e’ ratio was then calculated.
In two-dimensional (2D) mode, biplane left 
ventricular long-axis length at end diastole (LVLd) 
and biplane left ventricular long-axis length at 
end systole (LVLs) were calculated by averaging 
measurements from apical two-chamber and apical 
four-chamber views. The biplane technique of disk 
summation (modified Simpson’s rule) was used 
to calculate left ventricular end diastolic volume 
(EDV), left ventricular end systolic volume (ESV), 
left ventricular stroke volume (SV) and left ventricu-
lar ejection fraction (EF) in the 2D mode [20]. Right 
atrial dimension (RA), right ventricular basal and 
mid cavity dimensions (RVb and RVm, respectively) 
were measured on apical four-chamber view that 
was slightly focused on the right heart chambers. left 
atrial volume (LAV) and right atrial volume (RAV) 
were calculated using the area length method [20, 
21]. The change of LAV index (LAVI) was defined 
as the difference between follow-up and baseline 
LAVI (∆LAVI = follow-up LAVI – baseline LAVI). 
Similarly, the change of the E/e’ ratio was the dif-
ference between follow-up and baseline E/e’ ratio 
(∆E/e’ = follow-up E/e’ – baseline E/e’).
Figure 1. Ampalzer™ Cardiac plug and Amplazer™ Amulet; SW — stabilising wire.
Feature Ampalzer™ Cardiac Plug Amplazer™ Amulet
Size 16 18 20 22 24 26 28 30 16 18 20 22 25 28 31 34
Disc diameter Lobe + 4 mm Lobe + 6 mm Lobe + 6 mm Lobe + 7 mm
Lobe length 6.5 mm 7.5 mm 10 mm
Waist length 4 mm 5.5 mm 8 mm
SW diameter 0.006 inch 0.0065 inch
SW pairs 6 6 8 10
Sheath (Fr) 9 10 13 12 14
Proximal disc end-screw Protruding Recessed
Preparation Partly pre-load Fully pre-load
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Statistical analysis
To reduce the time-modified confounding ef-
fect, the difference-in-difference (DID) estimator 
was adopted to evaluate the impact of percutane-
ous LAAC on cardiac remodeling among NVAF 
patients [22, 23]. The analysis focused on com-
paring cardiac functional and structural changes 
that occurred between baseline and follow-up in 
both intervention (LAAC group) and control (non-
LAAC group) groups. The model that was used for 
this DID regression is written as: Yit = b0+ b1Gi+ 
b2Tt+b3GiTt+eit, where, Yit is the parameter Y in 
participant i measured at time t (baseline or follow-
up); b0 is a constant; Gi is a dummy that indicates 
whether this participant was in the LAAC group 
(Gi = 1) or in the non-LAAC group (Gi = 0); Tt is 
a dummy that indicates whether the parameter 
was measured at the follow-up (Tt = 1) or at the 
baseline (Tt = 0); eit represents the controlled vari-
ables. The main parameter of interest was b3 (the 
DID estimator), which indicated whether LAAC 
patients had more cardiac functional and structural 
changes over time than the NVAF patients without 
LAAC. The DID estimator revealed the real ef-
fect of LAAC on cardiac functional and structural 
remodeling after removing the effect of factors 
related to the time trend such as aging, disease 
progression, social life change, new medication, 
and other factors. 
Statistical analyses were performed using 
SPSS Statistics 23.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables were presented as 
the mean ± standard deviation. Categorical vari-
ables were presented as frequencies and percent-
ages. The c2 test was used to compare categorical 
variables, and for independent samples T-test was 
used to compare continuous variables. Multiple 
regression with the stepwise method was used to 
identify independent predictors of cardiac remod-
eling in the LAAC group, which had a significant 
association recognized using univariate analysis. 
A two-sided p value < 0.05 was considered statisti-
cally significant. 
Results
Out of 188 NVAF patients who were included 
in this study, 47 were in the LAAC group, and 141 
were in the non-LAAC group. The baseline char-
acteristics of the participants are summarized in 
Table 1. There were no statistically significant dif-
ferences in age, sex, body mass index, EF and cardi-
othoracic ratio between the two groups. The HAS-
BLED score, the CHA2DS2-VASc score and the rate 
of stroke history were higher in the LAAC group 
than that in the non-LAAC group. However, these 
differences were also statistically insignificant. 
The mean procedure time was 94.2 ± 42.9 min, 
Table 1. The baseline characteristics of participants.
Variable LAAC group (n = 47) Non-LAAC group (n = 141) P
Age [year] 75.1 ± 9.9 74.7 ± 9.7 0.799
Male gender 20 (42.6%) 60 (42.6%) 1.000
BMI [kg/m2] 24.4 ± 3.8 24.3 ± 3.7 0.953
HAS-BLED score 2.55 ± 1.41 2.23 ± 1.34 0.156
CHA2DS2-VASc score 3.83 ± 1.98 3.32 ± 1.65 0.082
Labile INR 6 (12.8%) 20 (14.2%) 0.807
Bleeding 8 (17.0%) 23 (16.3%) 0.910
Stroke or TIA 21 (44.7%) 49 (34.8%) 0.223
Hypertension 32 (68.1%) 92 (65.2%) 0.722
Diabetes mellitus 6 (12.8%) 21 (14.9%) 0.719
Congestive heart failure 14 (29.8%) 35 (24.8%) 0.502
Chronic kidney disease 5 (10.6%) 13 (9.2%) 0.775
Vascular diseases 7 (14.9%) 14 (9.9%) 0.349
Heart rate [bpm] 78.0 ± 16.9 80.4 ± 18.1 0.429
Cardiothoracic ratio 0.58 ± 0.06 0.59 ± 0.07 0.538
Left ventricular ejection fraction 56.7 ± 10.8 55.4 ± 11.7 0.425
LAAC — left atrial appendage closure; BMI — body mass index; INR — international normalized ratio; TIA — transient ischemic attack
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and Cardiac Plug was used in 30 (66.0%) pa- 
tients.
The impact of LAAC on cardiac structural 
remodeling is demonstrated in Table 2. There 
was no significant difference in structural change 
of left ventricle, right ventricle and right atrium 
between the two groups. However, the LAAC 
group had a higher relative increase in LAD, LAV 
and LAVI than the non-LAAC group with positive 
DID estimators (+3.9 mm, p = 0.001; +9.7 mL, 
p = 0.006 and +5.9 mL/m2, p = 0.011, respec-
tively).
The impact of LAAC on cardiac functional 
remodeling is presented in Table 3. In comparison 
with the non-LAAC group, EF and fractional short-
ening had more relative decrease among LAAC 
patients with a negative DID estimator, but these 
changes were statistically insignificant (–3.5%, 
p = 0.109 and –2.0%, p = 0.167, respectively). Ad-
ditionally, there was a significant relative increase 
in E and E/e’ ratio observed in patients with LAAC 
(+14.6 cm/s, p = 0.002 and +2.3, p = 0.028, re-
spectively).
Univariate analysis showed that the rela-
tive LAVI change in the LAAC group was as-
sociated with baseline LAD (b = –0. 56, p < 
< 0.001), IVSd (b = –0.33, p < 0.05); RVm 
(b = –0.35, p < 0.05), E (b = –0.38, p < 0.05) and 
pulmonary arterial systolic pressure (b = –0.29, 
p < 0.05). Besides, the relative change of the 
E/e’ ratio was correlated with IVSd (b = –0.34, 
p < 0.05), LVPWd (b = –0.49, p < 0.001), LVM 
(b = –0.29, p < 0.05) and RVm (b = –0.30, p < 0.05). 
In multiple linear regression with the step-
wise method, the predictor of the relative LAVI 
change was baseline LAD (b = –0.94, p < 0.001, 
Table 2. Changes on cardiac configuration evaluated by difference-in-difference (DID) analysis.
Parameters LAAC group (n = 47) Non-LAAC group (n = 141) DID  
estimator
95% CI P
Baseline Follow-up Baseline Follow-up
M-mode 
LAD [mm] 48.2 ± 8.7 53.6 ± 9.0 49.9 ± 8.5 51.3 ± 8.6 +3.9 1.9; 5.8 0.001
LVDd [mm] 51.1 ± 5.5 50.8 ± 5.7 51.1 ± 6.3 50.7 ± 6.5 +0.7 –1.1; 1.7 0.685
LVDs [mm] 34.6 ± 6.2 35.7 ± 6.7 34.1 ± 7.0 33.5 ± 7.5 +1.7 –0.1; 3.5 0.064
IVSd [mm] 9.5 ± 1.3 9.2 ± 1.0 10.0 ± 1.6 9.7 ± 1.6 -0.2 –0.6; 0.3 0.447
IVSs [mm] 13.5 ± 2.1 13.0 ± 1.5 14.2 ± 2.5 14.1 ± 2.6 –0.4 –1.2; 0.4 0.298
LVPWd [mm] 9.3 ± 1.2 8.9 ± 0.9 9.3 ± 1.2 9.5 ± 3.2 –0.4 –1.4; 0.6 0.398
LVPWs [mm] 14.1 ± 2.5 13.4 ± 2.1 14.5 ± 2.4 14.4 ± 2.4 –0.6 –1.5; 0.3 0.209
2D-mode 
LVLd [mm] 73.9 ± 8.1 72.4 ± 6.2 74.5 ± 9.2 74.2 ± 9.1 –0.9 –2.9; 1.1 0.383
LVLs [mm] 64.6 ± 7.8 62.2 ± 6.2 65.1 ± 8.3 64.3 ± 8.2 –1.6 –3.9; 0.6 0.154
RVb [mm] 33.3 ± 8.3 34.5 ± 4.6 34.0 ± 5.0 35.0 ± 6.9 +0.2 –2.4; 2.8 0.887
RVm [mm] 22.3 ± 3.4 22.7 ± 3.0 22.2 ± 2.7 23.5 ± 4.9 –0.9 –2.6; 0.7 0.262
RAD [mm] 40.8 ± 8.8 40.7 ± 5.7 43.3 ± 8.4 44.0 ± 9.1 –0.9 –3.9; 2.4 0.589
Volume and mass 
EDV [mL] 99.4 ± 29.4 101.3 ± 29.2 104.6 ± 37.3 107.6 ± 46.4 –1.6 –10.5; 7.3 0.722
ESV [mL] 39.1 ± 19.9 41.0 ± 29.1 42.3 ± 23.0 43.5 ± 29.5 +0.3 –5.8; 6.4 0.926
SV [mL] 47.0 ± 16.0 46.8 ± 12.2 48.4 ± 18.3 49.8 ± 18.5 –1.5 –6.5; 3.4 0.540
LAV [mL] 90.3 ± 36.7 108.4 ± 37.7 95.9 ± 35.9 104.2 ± 44.9 +9.7 3.6; 15.9 0.006
LAVI [mL/m2] 54.7 ± 23.0 68.1 ± 23.5 60.0 ± 24.4 67.5 ± 31.4 +5.9 1.7; 9.8 0.011
RAV [mL] 67.1 ± 39.1 62.3 ± 17.8 78.4 ± 40.6 76.1 ± 50.8 –1.8 –13.8; 10.2 0.764
LVM [g] 173.6 ± 46.3 162.1 ± 33.8 181.5 ± 50.1 176.4 ± 49.5 –6.4 –17.3; 4.5 0.246
LVMI [g/m2] 107.2 ± 26.3 100.2 ± 21.6 110.4 ± 31.0 107.9 ± 29.2 –4.6 –10.8; 3.1 0.280
LAAC — left atrial appendage closure; CI — confidence interval; LAD — left atrial dimension; LVDd/LVDs — left ventricular internal dimension 
at end diastole/systole; IVSd/IVSs — interventricular septum thickness at end diastole/systole; LVPWd/LVPWs — left ventricular posterior 
wall thickness at end diastole/systole; LVLd/LVLs — biplane left ventricular diastolic/systolic length; RVb/RBm — right ventricular base/middle 
dimension; RAD — right atrial dimension; EDV/ESV — biplane left ventricular volume at end diastole/systole; SV — biplane left ventricular 
stroke volume; LAV — left atrial volume; LAVI — left atrial volume indexed to body surface area; RAV — right atrial volume; LVM — left  
ventricular mass; LVMI — left ventricular mass index
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R = 0.55), and the predictor of the relative E/e’ 
ratio change was baseline LVPWd (b = –2.23, 
p < 0.01, R = 0.477).
Discussion
The present study showed that there were 
several impacts of LAAC on cardiac functional and 
structural remodeling in NVAF patients. Significant 
increases were identified in LA size and LV filling 
pressure in this group of patients 12 months after 
the procedure. 
Percutaneous LAAC is sometimes the only 
option for ischemic stroke prevention, especially 
in NVAF patients with contraindication for long-
term OAC or high risk of bleeding. Although the 
safety and efficacy of this treatment have been 
demonstrated in randomized controlled trials and 
real-world experience [5–7, 24, 25], the data about 
the impacts of LAAC on cardiac remodeling are 
not well established. To evaluate the impact of 
this therapy on cardiac functional and structural 
remodeling,  changes were measured and compared 
of echocardiographic parameters between LAAC 
and non-LAAC groups before and 12 months sub-
sequent to the procedure. 
A remarkable finding in this study was noted, 
a significantly higher increase in LAD (+3.9 mm), 
which may predictably lead to a higher increase in 
LAV (+9.7 mL) and the LAVI (+5.9 mL/m2) among 
LAAC patients after the procedure in comparison 
with non-LAAC patients (Fig. 2A, B). This LA 
remodeling  may be explained by the alteration of 
LAA function after LAAC. Previous studies have 
shown that there was a decrease in ANP concen-
tration after percutaneous LAA device closure for 
ischemic stroke prevention [15, 17]. Even though 
the mechanism of this phenomenon has not been 
fully understood, the insufficiency of this endocrine 
hormone may let the LA suffer more from pres-
sure and volume overload. Besides, LAA is more 
compliant than the LA main chamber and plays 
an important role in the presence of LA pressure 
and/or volume overload [26, 27]. The separation 
between LAA and LA after complete endotheliali-
zation of the device results in the disappearance of 
this LAA reservoir function [14]. An animal study 
has shown that LA compliance decreased after 
removal of the LAA, and the change in compliance 
was associated with decreased atrial reservoir 
function, which was manifested by smaller reser-
voir volume alterations [13]. Furthermore, LAA 
clamping during coronary artery bypass grafting or 
mitral valve surgery indicated a significant increase 
in LA maximal dimension [14]. A recent study that 
evaluated the impact of LAAC on LA mechanical 
Table 3. Changes on cardiac function and pulmonary arterial pressure evaluated by  
difference-in-difference (DID) analysis.
Parameters LAAC group  
(n = 47)
Non-LAAC group  
(n = 141)
DID  
estimator
95% CI P
Baseline End-line Baseline End-line
Systolic function
FS [%] 32.3 ± 7.7 31.2 ± 7.1 33.4 ± 8.2 34.3 ± 8.3 –2.0 –4.9; 0.9 0.167
EF [%] 63.1 ± 12.1 60.1 ± 11.2 64.3 ± 12.3 64.8 ± 12.2 –3.5 –7.7; 0.8 0.109
EF2C [%] 58.9 ± 10.9 56.6 ± 9.5 55.3 ± 12.4 55.8 ± 11.1 –2.9 –6.6; 0.7 0.111
EF4C [%] 56.5 ± 12.4 55.2 ± 9.9 55.2 ± 11.0 55.6 ± 10.2 –1.4 –4.8; 1.9 0.404
EFBP [%] 57.7 ± 10.8 55.8 ± 9.2 55.4 ± 11.7 55.7 ± 10.1 –2.2 –5.3; 0.9 0.164
TAPSE [mm] 11.7 ± 2.2 12.0 ± 1.7 11.9 ± 2.3 11.9 ± 2.4 +0.4 –0.7; 1.4 0.476
Diastolic function
DT [ms] 183.5 ± 73.1 181.0 ± 73.1 182.8 ± 75.3 182.7 ± 71.8 –3.79 –36.8; 29.3 0.819
E [cm/s] 85.6 ± 28.4 106.1 ± 27.3 89.5 ± 26.9 95.3 ± 28.8 +14.6 6.18; 22.9 0.002
E/e’ ratio 14.3 ± 6.9 18.4 ± 7.8 14.4 ± 7.3 16.2 ± 7.3 +2.3 0.3; 4.3 0.028
Pulmonary arterial pressure
PAPs 39.1 ± 11.0 40.1 ± 9.5 39.2 ± 10.9 40.0 ± 12.8 +0.24 –3.7; 4.2 0.903
LAAC — left atrial appendage closure; CI — confidence interval; FS — left ventricular fractional shortening; EF — left ventricular ejection  
fraction on M-mode; EF2C — left ventricular ejection fraction on two chamber view; EF4C — left ventricular ejection fraction on four chamber 
view; EFBP — biplane left ventricular ejection fraction measured; TAPSE — tricuspid annular plane systolic excursion; DT — deceleration time 
of early diastolic trans-mitral flow; E — peak velocity of early diastolic trans-mitral flow; e’ — peak velocity of early diastolic mitral annular motion; 
PAPs — pulmonary arterial systolic pressure
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function also found that there was an increase in 
maximum LAV, LAVI and expansion index among 
NVAF patients who received this treatment [28]. 
However, these studies presented the alteration 
of LAD and LAV in a short time period, rang-
ing from hours to 60 days. Another study used 
3D-echocardiographic measurements in patients 
6 months after LAAC with Watchman device and 
showed that LAV increased significantly after in-
terventional LAAC. However, the LA enlargement 
did not correlate with clinical progression of heart 
failure [29]. In the present study, a similar conse-
quence of LAA isolation, related to the increase 
in LA size, could be observed 12 months after 
LAAC procedure. Furthermore, multiple linear 
regression with the stepwise method showed that 
the predictor of LAVI change was baseline LAD 
(b = –0.94, p < 0.001, R = 0.545). Interestingly, the 
negative correlation suggested that if LA had had 
a more normal appearance at the baseline (smaller 
LA size), then it would be more impacted after the 
LAAC (Fig. 3A). Thus, clinicians should be more 
careful in selecting patients with a less remodeled 
LA for LAAC. In addition, it may be necessary to 
pay more attention to medical therapy and follow-
up for this subgroup of patients after the procedure 
to reduce LA adverse remodeling.
Another important finding in the present 
study was a significant increase in the E/e’ ratio, 
which indicated an increase in LV filling pressure 
among patients with LAAC (Fig. 2D). In AF, atrial 
contraction is lost, Doppler assessment of LV filling 
pressure is limited by the variability in cycle length 
and the absence of organized atrial activity [19, 30]. 
However, echocardiographic parameters that are 
independent of atrial influence can be utilized to 
assess LV filling pressure in AF patients. Among 
these parameters, the E/e’ ratio was documented 
Figure 2. A–C. Changes in cardiac function and structure between baseline and follow-up; LA — left atrial; LAVI — left 
atrial volume indexed to body surface area; E — peak velocity of early diastolic trans-mitral flow; e’ — peak velocity of 
early diastolic mitral annular motion; DID — difference-in-difference analysis; LAAC — left atrial appendage closure.
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to have a most reliable correlation with invasive 
assessment of LV filling pressure [19, 31, 32]. Thus, 
the increase of the E/e’ ratio in the present study 
was a reliable manifestation of LV filling pressures 
elevation among AF patients after LAAC. This 
may be a consequence of inadequate volume and 
pressure regulation in LA because of LAA function 
loss following LAAC procedure. Previous studies 
confirmed that clamping or surgical excision of the 
appendage resulted in an immediate increase in 
mean atrial pressure [13, 27]. Besides, the elevated 
LV filling pressure in AF patients, which was esti-
mated by E/e’, was also found to be independently 
associated with atrial remodeling [33]. Therefore, 
the elevation of LV filling pressure was a good 
explanation for the increase in LAD and LAV after 
LAAC in this study [34–36]. Further analysis with 
multivariable regression showed that the change of 
LV filling pressure in LAAC group, represented by 
the E/e’ ratio, was independently associated with 
LVPWd (b= –2.23, p < 0.01, R = 0.477) (Fig. 3B). 
Besides, the correlation of the E/e’ ratio with IVSd, 
LVPWd, LVM in univariate analysis suggested the 
important role of baseline LV wall thickness in the 
alteration of LV filling pressure after LAAC.
The result of this study also showed no sig-
nificant change in LV and RV systolic function. 
However, all of the negative DID estimators of 
EF and fractional shortening change may elicit the 
decrease in systolic function among NVAF patients 
after LAAC. Along with increase in LA size and 
LV filling pressure, these changes may have some 
long-term physiological and clinical implications 
that need to be addressed.  
Limitations of the study
This was a retrospective study with a limited 
number of patients in the LAAC group. Observed 
changes may be caused by chance in this small 
study cohort. Furthermore, because only some 
relevant indicators related to cardiac remodeling 
were collected, the alteration of other parameters 
as well as clinical presentations may have happened 
and were not observed in this study. Similarly, 
changes in medication that may affect cardiac 
remodeling was not evaluated. Besides, patients 
were not matched for LA size at baseline, which 
may differently affect cardiac remodeling. Because 
the study population had a normal EF and elevated 
LV filling pressure at baseline, the results may only 
be specific to this population.
Conclusions
The present study showed that there was a sig-
nificant increase in LA size and LV filling pressure 
among NVAF patients after LAAC. These impacts 
of LAAC on cardiac functional and structural re-
Figure 3. A, B. Correlation between cardiac function and configuration changes with corresponding independent 
predictors; LAVI — left atrial volume indexed body surface area; e — peak velocity of early diastolic transmitral flow; 
e’ — peak velocity of early diastolic mitral annular motion; LAD — left atrial dimension; LVPWd — left ventricular 
posterior wall thickness at end diastole; DLAVI = follow-up LAVI – baseline LAVI; E/e’ = follow-up E/e’ – baseline E/e’.
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modeling observed on echocardiography may have 
clinical implications that need to be addressed in 
future studies. 
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